<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633175</url>
  </required_header>
  <id_info>
    <org_study_id>progesterone</org_study_id>
    <nct_id>NCT03633175</nct_id>
  </id_info>
  <brief_title>Progesterone in Patients With Placenta Previa</brief_title>
  <official_title>Efficacy of Prophylactic Vaginal Progesterone in Prevention of Preterm Delivery in Women With Placenta Previa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of prophylactic vaginal progesterone administration in
      reducing of the episodes of antepartum hemorrhage and subsequent prevention of preterm
      delivery in women with placenta previa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women who consent to participate in the study are randomly allocated into one of the
      two study groups. Women who are allocated to the study group will receive vaginal
      progesterone 400 mg [Prontogest速 vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed
      time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which
      is closer); while the other group will serve as controls. Patients will be followed up till
      delivery for the incidence in antepartum hemorrhagic episodes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of preterm delivery due to severe antepartum hemorrhage.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Number of patients who delivered before 37 weeks gestational age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No. of episodes of antepartum hemorrhage.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Mean number of episodes of antepartum hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for significant antepartum hemorrhage.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Number of patients requiring hospital admission for significant antepartum hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for threatened preterm labor.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Number of patients requiring hospital admission for threatened preterm labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Number of patients requiring blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe postpartum hemorrhage.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Number of patients who had severe postpartum hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cesarean hysterectomy.</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>Number of patients who underwent cesarean hysterectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>measured as mean number of doses of vaginal progesterone missed per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction: Likert Scale</measure>
    <time_frame>from 26 weeks till 37 weeks</time_frame>
    <description>measured according to the 5-grade Likert scale: very unsatisfied, unsatisfied, indifferent, satisfied and very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Birth weight.</measure>
    <time_frame>At birth</time_frame>
    <description>measured in Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for NICU admission and its duration.</measure>
    <time_frame>At birth</time_frame>
    <description>Number of neonates needing NICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory morbidity (transient tachypnea or respiratory distress syndrome).</measure>
    <time_frame>At birth</time_frame>
    <description>number of neonates with respiratory morbidities (transient tachypnea or respiratory distress syndrome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prematurity-related mortality.</measure>
    <time_frame>28 days postpartum</time_frame>
    <description>Number of neonates dying due to prematurity-related cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Placenta Previa</condition>
  <arm_group>
    <arm_group_label>Vaginal progesterone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive vaginal progesterone 400 mg [Prontogest速 vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal progesterone</intervention_name>
    <description>400 mg vaginal progesterone [Prontogest速 vaginal pessaries 400, Marcyrl, Cairo, Egypt] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).</description>
    <arm_group_label>Vaginal progesterone group</arm_group_label>
    <other_name>Prontogest速 suppositories</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gestational age 26-28 weeks of gestation.

          2. Definite and reliable diagnosis of placenta previa (defined as presence of a placenta
             within 2 cm of the internal os), using a transvaginal ultrasound scan.

        Exclusion Criteria:

          1. Multiple pregnancy.

          2. Women at high risk of preterm labor e.g. history of spontaneous preterm labor or
             preterm prelabor rupture of the membranes (PPROM).

          3. Severe antepartum hemorrhage and/or hemodynamic instability that necessitates urgent
             intervention and delivery.

          4. Women who have been maintained on progestin therapy since early pregnancy for whatever
             reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Samy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M Samy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Samy, MD</last_name>
    <phone>01001947488</phone>
    <email>mohammedsamy8132@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain SHams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbaseya</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Samy, MD</last_name>
      <phone>01001947488</phone>
      <email>mohammedsamy8132@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>mohammed mahmoud samy</investigator_full_name>
    <investigator_title>Lecturer in Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

